The Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes yesterday reported results for the six months to May 2015. During and after the period, the company has made significant progress on its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, and wellbeing companies. The commercial agreements signed, and expected ongoing scientific progress, leads us to expect that revenue
28 Aug 2015
From Science to Sales
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
From Science to Sales
OptiBiotix Health PLC (OPTI:LON) | 18.0 0 0.0% | Mkt Cap: 17.6m
- Published:
28 Aug 2015 -
Author:
Derren Nathan -
Pages:
6
The Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes yesterday reported results for the six months to May 2015. During and after the period, the company has made significant progress on its strategy of developing compounds which modify the human microbiome and commercialising these through partnering with food, health, and wellbeing companies. The commercial agreements signed, and expected ongoing scientific progress, leads us to expect that revenue